Trial Profile
A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Tasadenoturev (Primary) ; Interferon gamma
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- Acronyms TARGET-I
- Sponsors DNAtrix
- 23 Sep 2023 Results assessing the impact of neutralizing antibodies developed in patients during a phase 1 clinical trial of Delta-24-RGD for the treatment of recurrent malignant gliomas, presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.
- 12 Jul 2018 Status changed from active, no longer recruiting to completed.
- 30 Jan 2018 Planned primary completion date changed from 1 Aug 2017 to 15 Mar 2018.